Nasal Decongestants Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Nasal Decongestants. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Nasal Decongestants Indian Medical PG Question 1: Which of the following actions is NOT associated with tricyclic antidepressants?
- A. Block 5-HT or NE reuptake
- B. Anticholinergic action
- C. MAO inhibition (Correct Answer)
- D. Causes sedation
Nasal Decongestants Explanation: ***MAO inhibition***
- Tricyclic antidepressants (TCAs) primarily exert their effects by inhibiting the reuptake of **norepinephrine** and **serotonin**, not by inhibiting monoamine oxidase (MAO).
- **MAO inhibitors** are a distinct class of antidepressants with a different mechanism of action and side effect profile.
*Anticholinergic action*
- Many TCAs have significant **anticholinergic effects**, blocking muscarinic receptors and leading to side effects like dry mouth, constipation, and blurred vision.
- These effects contribute to the **adverse event profile** of TCAs, especially in elderly patients.
*Block 5-HT or NE reuptake*
- The primary mechanism of action of TCAs involves the **inhibition of serotonin (5-HT)** and **norepinephrine (NE) reuptake** into presynaptic neurons.
- This action increases the concentration of these neurotransmitters in the **synaptic cleft**, thereby potentiating their effects.
*Causes sedation*
- TCAs frequently cause **sedation**, particularly the more histaminergic ones (e.g., amitriptyline, doxepin), due to their **histamine H1 receptor antagonism**.
- This side effect can be beneficial for patients with insomnia but can be problematic for daytime functioning.
Nasal Decongestants Indian Medical PG Question 2: Epinephrine not used in:
- A. Uveitis glaucoma
- B. Aphakic glaucoma (Correct Answer)
- C. Open angle glaucoma
- D. Neovascular glaucoma
Nasal Decongestants Explanation: ***Aphakic glaucoma***
- Epinephrine is **contraindicated** in aphakic eyes due to the risk of developing **cystoid macular edema (CME)**, which can significantly impair vision.
- The mechanism of CME in aphakic eyes treated with epinephrine is thought to involve increased vascular permeability in the macula.
*Uveitis glaucoma*
- Topical epinephrine can be used in some cases of uveitic glaucoma to reduce **intraocular pressure (IOP)** by decreasing aqueous humor production and increasing uveoscleral outflow.
- However, its use requires careful consideration due to the potential for exacerbating ocular inflammation in some patients.
*Open angle glaucoma*
- Epinephrine (and its prodrug, dipivefrin) was historically used in the treatment of **open-angle glaucoma** to lower IOP.
- It acts by stimulating alpha- and beta-adrenergic receptors, leading to decreased aqueous production and increased outflow.
*Neovascular glaucoma*
- While traditionally not a primary treatment, epinephrine can sometimes be used as an **adjunctive therapy** in neovascular glaucoma to help lower IOP, as it reduces aqueous humor production.
- The primary treatment for neovascular glaucoma involves addressing the underlying cause of **neovascularization**, usually through panretinal photocoagulation or anti-VEGF injections.
Nasal Decongestants Indian Medical PG Question 3: Vidian neurectomy is used for the treatment of?
- A. Chronic vasomotor rhinitis (Correct Answer)
- B. Meniere's disease
- C. Otosclerosis
- D. Benign positional paroxysmal vertigo
Nasal Decongestants Explanation: ***Chronic vasomotor rhinitis***
- **Vidian neurectomy** is a surgical procedure that targets the **vidian nerve** (also known as the **nerve of the pterygoid canal**), which carries parasympathetic fibers to the nasal mucosa.
- By severing these fibers, the procedure aims to reduce the excessive nasal secretions and congestion characteristic of **vasomotor rhinitis**.
*Benign positional paroxysmal vertigo*
- This condition is primarily treated with **canalith repositioning maneuvers** (e.g., Epley maneuver), which aim to displace otoconia from the semicircular canals.
- Surgical intervention is rarely required and, if so, would typically involve **posterior semicircular canal occlusion**, not vidian neurectomy.
*Meniere's disease*
- Management often involves dietary modifications, medications (e.g., diuretics, anti-emetics), and, in severe cases, procedures like **endolymphatic sac decompression** or **labyrinthectomy**.
- **Vidian neurectomy** is not a treatment for the fluctuating hearing loss, vertigo, and tinnitus associated with Meniere's disease.
*Otosclerosis*
- The primary treatment for this condition, characterized by abnormal bone growth in the middle ear causing conductive hearing loss, is **stapedectomy** with prosthesis placement.
- **Vidian neurectomy** has no role in addressing the bony pathology of otosclerosis.
Nasal Decongestants Indian Medical PG Question 4: In patients taking tadalafil, the most serious drug interaction occurs with:
- A. Alpha-Blockers
- B. Ketoconazole
- C. Rifampicin
- D. Nitrates (Correct Answer)
Nasal Decongestants Explanation: ***Nitrates***
- The co-administration of **tadalafil** (a PDE5 inhibitor) with **nitrates** can cause a dangerous and potentially fatal drop in **blood pressure**.
- Both drug classes lead to increased cGMP levels, resulting in excessive **vasodilation** and profound **hypotension**.
*Alpha-Blockers*
- Alpha-blockers, while able to cause **hypotension** when taken with tadalafil, generally lead to less severe interactions than nitrates.
- The combination requires caution and potentially dose adjustments, but typically does not result in the same life-threatening blood pressure drops as seen with nitrates.
*Ketoconazole*
- **Ketoconazole** is a strong **CYP3A4 inhibitor**, which can increase the plasma concentration of tadalafil.
- This interaction can potentiate tadalafil's effects and increase the risk of side effects, but it doesn't create an immediate, life-threatening hypotensive crisis like nitrates.
*Rifampicin*
- **Rifampicin** is a potent **CYP3A4 inducer**, which can significantly decrease the plasma concentration of tadalafil.
- This interaction primarily leads to a **reduced efficacy** of tadalafil, rather than a dangerous increase in adverse effects or a severe drug-drug interaction.
Nasal Decongestants Indian Medical PG Question 5: A 30-year-old woman with a history of allergic rhinitis presents with bilateral watery nasal discharge and itchy eyes. What is the most appropriate first-line treatment?
- A. Nasal saline irrigation
- B. Antibiotics
- C. Oral antihistamine
- D. Intranasal corticosteroids (Correct Answer)
Nasal Decongestants Explanation: **Intranasal corticosteroids**
- **Intranasal corticosteroids** are considered the **first-line treatment** for allergic rhinitis due to their broad anti-inflammatory effects on nasal mucosa [1].
- They effectively reduce symptoms such as **nasal congestion**, **rhinorrhea**, **sneezing**, and **itching** [1].
*Nasal saline irrigation*
- **Nasal saline irrigation** can help clear irritants and mucus from the nasal passages, providing symptomatic relief.
- However, it is primarily an **adjunctive therapy** and not the most potent first-line treatment for managing moderate to severe allergic rhinitis symptoms alone.
*Antibiotics*
- **Antibiotics** are used to treat bacterial infections, which are not indicated in this case as the symptoms (watery discharge, itchy eyes) are classic for **allergic rhinitis**, not a bacterial infection.
- Unnecessary antibiotic use contributes to **antibiotic resistance** and provides no benefit for allergic conditions.
*Oral antihistamine*
- **Oral antihistamines** are effective for relieving sneezing, itching, and rhinorrhea in allergic rhinitis [1].
- While useful, intranasal corticosteroids generally offer **superior efficacy**, particularly for nasal congestion, and are often preferred as initial monotherapy for persistent symptoms [1].
Nasal Decongestants Indian Medical PG Question 6: Match the following drugs in Column A with their contraindications in Column B.
| Column A | Column B |
| :-- | :-- |
| 1. Morphine | 1. QT prolongation |
| 2. Amiodarone | 2. Thromboembolism |
| 3. Vigabatrin | 3. Pregnancy |
| 4. Estrogen preparations | 4. Head injury |
- A. A-1, B-3, C-2, D-4
- B. A-4, B-1, C-3, D-2 (Correct Answer)
- C. A-3, B-2, C-4, D-1
- D. A-2, B-4, C-1, D-3
Nasal Decongestants Explanation: ***A-4, B-1, C-3, D-2***
- **Morphine** is contraindicated in **head injury** as it can increase intracranial pressure and mask neurological symptoms.
- **Amiodarone** is contraindicated in patients with **QT prolongation** due to its risk of inducing more severe arrhythmias like Torsades de Pointes.
- **Vigabatrin** is contraindicated during **pregnancy** due to its potential for teratogenicity and adverse effects on fetal development.
- **Estrogen preparations** are contraindicated in patients with a history of **thromboembolism** due to their increased risk of blood clot formation.
*A-1, B-3, C-2, D-4*
- This option incorrectly matches **Morphine** with QT prolongation and **Estrogen preparations** with head injury, which are not their primary contraindications.
- It also incorrectly links **Vigabatrin** with thromboembolism and **Amiodarone** with pregnancy.
*A-3, B-2, C-4, D-1*
- This choice incorrectly associates **Morphine** with pregnancy and **Vigabatrin** with head injury, which are not the most critical or direct contraindications.
- It also misaligns **Amiodarone** with thromboembolism and **Estrogen preparations** with QT prolongation.
*A-2, B-4, C-1, D-3*
- This option incorrectly matches **Morphine** with thromboembolism and **Amiodarone** with head injury, which are not their most significant contraindications.
- It also incorrectly links **Vigabatrin** with QT prolongation and **Estrogen preparations** with pregnancy.
Nasal Decongestants Indian Medical PG Question 7: How do antihistamines help in allergic rhinitis?
- A. inhibit prostaglandin synthesis to relieve itching.
- B. block histamine receptors to reduce symptoms. (Correct Answer)
- C. reduce inflammation by blocking leukotrienes.
- D. prevent the release of mast cell mediators.
Nasal Decongestants Explanation: **Correct Answer: Block histamine receptors to reduce symptoms.**
- Antihistamines work by competitively binding to **histamine H1 receptors**, preventing histamine from exerting its effects.
- This action directly reduces symptoms such as **sneezing**, **itching**, and **rhinorrhea** (runny nose) associated with allergic reactions.
- They act after histamine has been released by blocking its receptors on target tissues.
*Incorrect: Inhibit prostaglandin synthesis to relieve itching.*
- This mechanism of action is characteristic of **NSAIDs (non-steroidal anti-inflammatory drugs)**, which primarily target pain and inflammation, not the histamine-mediated symptoms of allergic rhinitis.
- While prostaglandins can contribute to inflammation, antihistamines do not act on their synthesis.
*Incorrect: Reduce inflammation by blocking leukotrienes.*
- This mechanism describes the action of **leukotriene receptor antagonists** (e.g., Montelukast), which are used in asthma and allergic rhinitis but are distinct from antihistamines.
- Leukotrienes are potent inflammatory mediators, and blocking them helps reduce inflammation and bronchoconstriction.
*Incorrect: Prevent the release of mast cell mediators.*
- This is the mechanism of **mast cell stabilizers** (e.g., cromolyn sodium), which prevent the degranulation of mast cells and the subsequent release of histamine and other inflammatory mediators.
- Antihistamines act after histamine has already been released, not before.
Nasal Decongestants Indian Medical PG Question 8: Which of the following is a contraindication to the use of beta-blockers?
- A. Glaucoma
- B. Tachycardia
- C. Hypertension
- D. Bronchial asthma (Correct Answer)
Nasal Decongestants Explanation: ***Bronchial asthma***
- Beta-blockers, especially non-selective ones, can cause **bronchoconstriction** by blocking beta-2 receptors in the lungs, worsening asthma symptoms.
- This can precipitate an **asthma exacerbation** or severe respiratory distress in susceptible individuals.
*Glaucoma*
- Beta-blockers are actually used in the treatment of glaucoma, as they **decrease aqueous humor production**, thereby lowering intraocular pressure.
- Thus, it is a **therapeutic indication**, not a contraindication.
*Tachycardia*
- Beta-blockers are frequently used to treat various forms of tachycardia by **slowing the heart rate** and reducing myocardial oxygen demand.
- They achieve this by blocking beta-1 receptors in the heart, making tachycardia an **indication** rather than a contraindication.
*Hypertension*
- Beta-blockers are a well-established class of drugs for the treatment of hypertension, as they **reduce blood pressure** by various mechanisms, including decreasing heart rate and cardiac output.
- Therefore, hypertension is an **indication** for beta-blocker use, not a contraindication.
Nasal Decongestants Indian Medical PG Question 9: True regarding rhinitis medicamentosa is/are?
- A. Caused by beta-agonist sprays
- B. Prolonged spray use can cause turbinate hypertrophy
- C. Caused by adrenergic agonist decongestants (Correct Answer)
- D. There is inferior turbinate hypertrophy
Nasal Decongestants Explanation: ***Caused by adrenergic agonist decongestants***
- **Rhinitis medicamentosa** is a condition of nasal congestion caused by the overuse of topical **alpha-adrenergic agonist decongestant** nasal sprays like oxymetazoline or phenylephrine (NOT beta-agonists).
- These decongestants cause **vasoconstriction**, and their prolonged use (typically >5-7 days) leads to a **rebound phenomenon** of vasodilation and worsening congestion.
- This is the PRIMARY and DEFINING characteristic of rhinitis medicamentosa.
*Caused by beta-agonist sprays*
- Beta-agonist sprays are primarily used in the treatment of **asthma** and act on beta-adrenergic receptors in the bronchi.
- They do **NOT** cause rhinitis medicamentosa, which is specifically linked to **alpha-adrenergic agonists** in the nasal mucosa.
**Prolonged spray use can cause turbinate hypertrophy**
- This statement is **ALSO MEDICALLY ACCURATE** - chronic use of topical decongestants leads to **mucosal edema, inflammation, and eventually structural turbinate hypertrophy**.
- The pathophysiology involves chronic vasodilation, mucosal inflammation, and eventual fibrosis.
- However, the PRIMARY defining feature remains the medication-induced rebound congestion from alpha-agonists.
**There is inferior turbinate hypertrophy**
- **Inferior turbinate hypertrophy** is indeed a **COMMON CLINICAL FINDING** in rhinitis medicamentosa on nasal endoscopy.
- The chronic congestion and inflammation lead to bilateral inferior turbinate enlargement with pale, boggy mucosa.
- However, this is a SECONDARY finding/complication rather than the PRIMARY defining characteristic.
**NOTE:** Both turbinate hypertrophy statements are medically accurate features of rhinitis medicamentosa. The primary/most specific answer is the etiology (alpha-adrenergic agonist decongestants).
Nasal Decongestants Indian Medical PG Question 10: A patient comes with a history of asthma and sinusitis. On looking into his medical records, you notice this has been attributed to Samter’s triad. Which drug should be avoided in this patient due to its potential to exacerbate respiratory symptoms?
- A. Cotrimoxazole
- B. Co-amoxiclav
- C. Chloramphenicol
- D. Aspirin (Correct Answer)
Nasal Decongestants Explanation: ***Aspirin (Correct Answer)***
- Samter's triad, or **aspirin-exacerbated respiratory disease (AERD)**, is characterized by **asthma**, **nasal polyps with chronic rhinosinusitis**, and a severe reaction to **aspirin** and other **NSAIDs**.
- **Aspirin** inhibits COX-1, leading to an overproduction of **leukotrienes**, which causes bronchoconstriction and exacerbates respiratory symptoms in susceptible individuals.
- This is the drug that **must be avoided** in patients with Samter's triad.
*Cotrimoxazole (Incorrect)*
- **Cotrimoxazole** (trimethoprim-sulfamethoxazole) is an antibiotic not directly involved in the cyclooxygenase pathway.
- While allergic reactions can occur, it is **not specifically contraindicated** in Samter's triad.
*Co-amoxiclav (Incorrect)*
- **Co-amoxiclav** (amoxicillin/clavulanic acid) is a penicillin-class antibiotic, and its mechanism of action does not involve prostaglandin synthesis.
- It does not pose a specific risk for exacerbating respiratory symptoms in patients with **Samter's triad**.
*Chloramphenicol (Incorrect)*
- **Chloramphenicol** is an antibiotic that inhibits bacterial protein synthesis and is not associated with the pathogenesis of Samter's triad.
- It does not impact the **cyclooxygenase or lipoxygenase pathways** that are central to AERD.
More Nasal Decongestants Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
